DK1853244T3 - Metode til behandling af præmatur retinopati og relaterede retinopatiske sygdomme - Google Patents

Metode til behandling af præmatur retinopati og relaterede retinopatiske sygdomme

Info

Publication number
DK1853244T3
DK1853244T3 DK06736134.5T DK06736134T DK1853244T3 DK 1853244 T3 DK1853244 T3 DK 1853244T3 DK 06736134 T DK06736134 T DK 06736134T DK 1853244 T3 DK1853244 T3 DK 1853244T3
Authority
DK
Denmark
Prior art keywords
cells
retina
retinopatic
diseases
pharmaceutical composition
Prior art date
Application number
DK06736134.5T
Other languages
English (en)
Inventor
Martin Friedlander
Eyal Banin
Edith Aguilar
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK1853244T3 publication Critical patent/DK1853244T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06736134.5T 2005-02-24 2006-02-24 Metode til behandling af præmatur retinopati og relaterede retinopatiske sygdomme DK1853244T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65612205P 2005-02-24 2005-02-24
PCT/US2006/006744 WO2006091895A2 (en) 2005-02-24 2006-02-24 Method for the treatment of retinopathy of prematurity and related retinopathic diseases

Publications (1)

Publication Number Publication Date
DK1853244T3 true DK1853244T3 (da) 2013-09-30

Family

ID=36928090

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07021593.4T DK1935976T3 (da) 2005-02-24 2006-02-24 Transficerede myeloid-lignende celler til behandling af retinopati ved for tidlig fødsel og dermed relaterede sygdomme
DK06736134.5T DK1853244T3 (da) 2005-02-24 2006-02-24 Metode til behandling af præmatur retinopati og relaterede retinopatiske sygdomme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07021593.4T DK1935976T3 (da) 2005-02-24 2006-02-24 Transficerede myeloid-lignende celler til behandling af retinopati ved for tidlig fødsel og dermed relaterede sygdomme

Country Status (13)

Country Link
US (1) US20080317721A1 (da)
EP (2) EP1853244B1 (da)
JP (1) JP5173442B2 (da)
CN (1) CN101356268A (da)
AT (1) ATE545697T1 (da)
AU (1) AU2006216473B2 (da)
CA (1) CA2599172A1 (da)
DK (2) DK1935976T3 (da)
ES (2) ES2382357T3 (da)
PL (1) PL1935976T3 (da)
PT (1) PT1935976E (da)
RU (1) RU2403906C2 (da)
WO (1) WO2006091895A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0608272A2 (pt) * 2005-02-24 2009-12-08 Scripps Research Inst método para promover revascularização fisiológica benéfica de tecido retinal isquêmico e método de triagem para identificar e avaliar a eficácia terapêutica de agentes terapêuticos potenciais para tratar doenças neovasculares retinais
CA2598029A1 (en) * 2005-02-24 2006-10-05 The Scripps Research Institute Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
WO2008006168A1 (en) * 2006-07-12 2008-01-17 Angioblast Systems, Inc. Treatment of excessive neovascularization
US8481313B2 (en) * 2008-04-22 2013-07-09 Regenerative Research Foundation Retinal pigment epithelial stem cells
WO2011159981A2 (en) * 2010-06-18 2011-12-22 Women And Infants Hospital Of Rhode Island Lung regeneration using cord blood-derived hematopoietic stem cells
RU2445944C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2445946C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2445943C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2445945C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2464958C2 (ru) * 2010-11-26 2012-10-27 Государственное учреждение здравоохранения Свердловской области детская клиническая больница восстановительного лечения "Научно-практический центр "Бонум" Способ хирургического лечения рубцовых стадий ретинопатии недоношенных
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
EP2838995A4 (en) * 2012-04-16 2016-01-06 Univ California EYE THERAPEUTICS WITH MICROVESICLES FROM EMBRYONAL STEM CELLS
RU2496871C1 (ru) * 2012-08-09 2013-10-27 Сергей Владимирович Осутин Способ выделения стволовых клеток из костного мозга для внутрисосудистого введения
CN107038704B (zh) * 2017-05-04 2020-11-06 季鑫 视网膜图像渗出区域分割方法、装置和计算设备
RU2729031C1 (ru) * 2020-03-13 2020-08-03 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ хирургического лечения пролиферативной диабетической ретинопатии, осложненной гемофтальмом и тракционной отслойкой сетчатки
US20230181686A1 (en) * 2020-05-27 2023-06-15 Baylor College Of Medicine Compositions and methods for treating neovascularization and ischemic retinopathies by targeting angiogenesis and cholesterol transport

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030161817A1 (en) * 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
WO2006031467A2 (en) * 2002-07-25 2006-03-23 The Scripps Research Institute Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US20060104963A1 (en) * 2002-07-25 2006-05-18 The Scripps Research Institute Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells
CA2493122C (en) * 2002-07-25 2012-11-27 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
RU2238705C1 (ru) * 2003-04-28 2004-10-27 Московский научно-исследовательский институт глазных болезний им. Гельмгольца Способ коррекции дистрофических изменений сетчатки при ее патологии различного генеза
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith

Also Published As

Publication number Publication date
ATE545697T1 (de) 2012-03-15
EP1853244B1 (en) 2013-07-17
AU2006216473B2 (en) 2012-07-26
WO2006091895A3 (en) 2008-09-12
JP2008536804A (ja) 2008-09-11
EP1935976A1 (en) 2008-06-25
PT1935976E (pt) 2012-05-15
EP1853244A4 (en) 2010-06-23
EP1853244A2 (en) 2007-11-14
JP5173442B2 (ja) 2013-04-03
ES2382357T3 (es) 2012-06-07
EP1935976B1 (en) 2012-02-15
DK1935976T3 (da) 2012-04-10
WO2006091895A2 (en) 2006-08-31
US20080317721A1 (en) 2008-12-25
RU2403906C2 (ru) 2010-11-20
CN101356268A (zh) 2009-01-28
RU2007135220A (ru) 2009-03-27
AU2006216473A1 (en) 2006-08-31
ES2427966T3 (es) 2013-11-05
PL1935976T3 (pl) 2012-07-31
CA2599172A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
DK1853244T3 (da) Metode til behandling af præmatur retinopati og relaterede retinopatiske sygdomme
Jiang et al. Nrf2/ARE is a key pathway for curcumin-mediated protection of TMJ chondrocytes from oxidative stress and inflammation
Yin et al. Exogenous hydrogen sulfide protects against global cerebral ischemia/reperfusion injury via its anti-oxidative, anti-inflammatory and anti-apoptotic effects in rats
ES2647368T3 (es) Inhibidores de HDAC para tratar la enfermedad de Charcot-Marie-Tooth
Quintanilla et al. Understanding risk factors for Alzheimer's disease: interplay of neuroinflammation, connexin-based communication and oxidative stress
CY1124074T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων
EA201170847A1 (ru) Тиазолопиридиновые соединения, регулирующие сиртуин
EA201071059A1 (ru) Способы и композиции для лечения воспаления и связанных с воспалением патологических состояний
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
NO20083885L (no) Fremgangsmate for behandling av inflammatoriske sykdommer
WO2008103993A3 (en) Compositions and methods for treating glycogen storage diseases
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
Naqvi et al. Curcumin lessens unpredictable chronic mild stress-induced depression and memory deficits by modulating oxidative stress and cholinergic activity
EA201100245A1 (ru) Новый холиновый сокристалл эпалрестата
UY39138A (es) Agentes de arni para inhibir la expresión de pnpla3, composiciones farmacéuticas de esta, y métodos de uso
CL2025001153A1 (es) Agentes de arni para inhibir la expresión de la proteína quinasa dm1 (dmpk)
Kumar et al. Cell death mechanisms in the early stages of acute glutamate neurotoxicity
Ottanà et al. Synthesis and in vitro evaluation of 5-arylidene-3-hydroxyalkyl-2-phenylimino-4-thiazolidinones with antidegenerative activity on human chondrocyte cultures
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
Bai et al. PRDX1 Cys52Ser variant alleviates nonalcoholic steatohepatitis by reducing inflammation in mice
Srejovic et al. The effects of the modulation of NMDA receptors by homocysteine thiolactone and dizocilpine on cardiodynamics and oxidative stress in isolated rat heart
Kalonia et al. Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats
Kalonia et al. Licofelone attenuates quinolinic acid induced Huntington like symptoms: possible behavioral, biochemical and cellular alterations
BRPI0506493A (pt) combinações terapêuticas
Kronsteiner et al. Kynurenic acid levels and kynurenine aminotransferase I, II and III activities in ganglia, heart and liver of snail Helix Pomatia